CORRELATION BETWEEN PSA LEVEL AND GLEASON SCORE IN NEWLY DIAGNOSED PROSTATE CANCER PATIENTS IN ARAD COUNTY

This is an automatically generated default intro template – please do not edit.

	Read full article
Article Title:	CORRELATION BETWEEN PSA LEVEL AND GLEASON SCORE IN NEWLY DIAGNOSED PROSTATE CANCER PATIENTS IN ARAD COUNTY
Authors:	Alin Grelus1,2,3†, Miklos Imola1,2†, Botezatu Dragos1,2,3, Muresanu Horia2,3, Crisan Adrian2,3 , Ioan Ioiart1,2,3
Affiliation:	1Institute of Life Sciences, “Vasile Goldis” Western University of Arad, Arad, RO 310045, Str. Liviu Rebreanu 86, Romania 2Arad County Emergency Clinical Hospital, Arad, RO 310037, Str. Andreny Karoly nr. 2 – 4, Romania 3Faculty of Pharmacy, “Vasile Goldis” Western University of Arad, Arad, RO 310045, Str. Liviu Rebreanu 86, Romania † These authors have contributed equally to this manuscript and should be considered as first authors.
Abstract:	Prostate carcinoma (PCa) is the second most common type of cancer among men from North America and Europe. Histopathological diagnosis of PCa can be established by transrectal ultrasound-guided (TRUS) biopsy after an abnormal finding in digital rectal examination or finding an increased value of prostate specific antigen (PSA) in the blood. The purpose of this study is to evaluate the correlation between PSA level and Gleason score, in order to predict prostate cancer aggressiveness at time of diagnosis.
Keywords:	prostate, cancer, PSA, Gleason, score.
References:	1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. [PubMed] 2. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D, Soerjomataram I. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer. 2015;51:1164–1187. [PubMed] 3. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and localtreatment with curative intent-update 2013. Eur Urol. 2014;65:124–137. [PubMed] 4. http://uroweb.org/guideline/prostate-cancer/#4 5. 5.https://books.google.ro/books?id=kpT2eIxOCi8C&pg=PA181&lpg=PA181&dq=arad+arsenic&source=bl&ots=EoCXZlJs5N&sig=RR9xP2UOG_Qe39pONDhF-W9mOg&hl=ro&sa=X&ved=0ahUKEwjOjLvEj7zbAhXIKJoKHfx-CSEQ6AEISDAF#v=onepage&q=arad%20arsenic&f=false 6. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29 7. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D, Soerjomataram I. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer. 2015;51:1164–1187. 8. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and localtreatment with curative intent-update 2013. Eur Urol. 2014;65:124–137. 9. Pepe P, Pennisi M, Gleason score stratification according to age at diagnosis, Cancer statistics, 2015. CA Cancer J Clin. 2015;64:9–29 10. Ioiart I.: Valoarea PSA-ului in depistarea si terapia cancerului de prostatic. Prostata, Vol. I, nr.2 pp. 14-18, 2001 11. Alan Wein A, et al. Campbell-Walsh Urology 11th Edition. Elsevier, 2015. 12. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014 Aug 6. [Medline]. 13. Hu JC, Williams SB, Carter SC, Eggener SE, Prasad S, Chamie K, et al. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2014 Jul 10. [Medline]. 14. American Urological Association. Prostate-Specific Antigen Best Practice Statement: 2009 Update. Accessed August 15, 2010. [Full Text].
*Correspondence:	alin_gvg@yahoo.com, miklosimola@gmail.com